Alx Oncology Holdings (ALXO) Equity Average (2019 - 2026)

Alx Oncology Holdings' Equity Average history runs 8 years deep, the most recent figure standing at $88.7 million for Q1 2026.

• In Q1 2026, Equity Average fell 12.18% year-over-year to $88.7 million; the TTM figure through Mar 2026 stood at $88.7 million (down 12.18% YoY), while the FY2025 annual figure was $69.8 million, down 53.98% from the prior year.
• Equity Average came in at $88.7 million for Q1 2026 at Alx Oncology Holdings, up from $35.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $353.3 million in Q1 2022 to a low of $35.4 million in Q4 2025.
• A 5-year average of $181.0 million and a median of $177.0 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average plunged 71.74% in 2025 and declined 12.18% in 2026, its largest moves.
• Alx Oncology Holdings' Equity Average stood at $275.2 million in 2022, then sank by 34.88% to $179.2 million in 2023, then tumbled by 30.14% to $125.2 million in 2024, then slumped by 71.74% to $35.4 million in 2025, then jumped by 150.53% to $88.7 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $88.7 million, $35.4 million, and $54.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison